¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"principle of least action"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • absorption action
    Èí¼öÀÛ¿ë
  • amphoteric action
    ¾çÂÊÀÛ¿ë
  • anabolic action
    ÇÕ¼º´ë»çÀÛ¿ë, µ¿È­ÀÛ¿ë
  • biphasic action potential
    ÀÌ»ó¼ºÈ°µ¿ÀüÀ§
  • bacteriocidal action
    »ì±ÕÀÛ¿ë
  • bacteriostatic action
    Á¤±ÕÀÛ¿ë
  • buffer action
    ¿ÏÃæÀÛ¿ë
  • competitive action
    °æÀïÀÛ¿ë
  • compound muscle action potential
    º¹ÇÕ±Ù(À°)Ȱµ¿ÀüÀ§
  • compound nerve action potential
    º¹ÇսŰæÈ°µ¿ÀüÀ§
  • corrective action
    ±³Á¤Ã³Ä¡
  • curariform action
    Äí¶ó·¹À¯»çÀÛ¿ë
  • chronotropic action
    ½É¹Ú¼öº¯µ¿ÀÛ¿ë
  • dual block action
    ÀÌÁßÂ÷´ÜÀÛ¿ë
  • dynamic action
    µ¿·ÂÀÛ¿ë
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • action potential
    Ȱµ¿ÀüÀ§
  • action tremor
    Ȱµ¿¶³¸²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antimicrobial action
    Ç×±ÕÀÛ¿ë
  • antipyretic action
    ÇØ¿­ÀÛ¿ë
  • bacteriocidal action
    »ì±ÕÀÛ¿ë
  • bacteriostatic action
    Á¤±ÕÀÛ¿ë
  • buffer action
    ¿ÏÃæÀÛ¿ë
  • chronotropic action
    ½É¹Ú¼öº¯µ¿ÀÛ¿ë
  • competitive action
    °æÀïÀÛ¿ë
  • corrective action
    ±³Á¤Ã³Ä¡
  • curariform action
    Äí¶ó·¹À¯»çÀÛ¿ë
  • diabetogenic action
    ´ç´¢º´À¯¹ßÀÛ¿ë
  • diastatic action
    ´çÈ­ÀÛ¿ë
  • dual block action
    ÀÌÁßÂ÷´ÜÀÛ¿ë
  • dynamic action
    µ¿·ÂÀÛ¿ë
  • gestagenic action
    ÇÁ·Î°Ô½ºÅ×·ÐÀÛ¿ë, Ȳüȣ¸£¸óÀÛ¿ë
  • immediate action
    Áï°¢ÀÛ¿ë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pulse echo principle
    ÆÞ½º ¿¡ÄÚ ¿ø¸®
  • pulse echo principle
    ÆÞ½º-¿¡ÄÚ ¿ø¸® (ê«×â)
  • reality principle
    Çö½Ç¿øÄ¢(úÞãùê«öÎ).
  • HT2 receptors, action of hallucinogens
    5-ÇÏÀ̵å·Ï½ÃÆ®¸³Å¸¹Î2¼ö¿ëü
  • SDA= specific dynamic action
    ƯÀ̵¿Àû ÀÛ¿ë.
  • absorption action
    Èí¼öÀÛ¿ë.
  • action myoclonia
    Ȱµ¿°£´ë¼º ±Ù°æ·Ã(Áõ)(¡­ÊàÓÛàõÐÉÌâÕýñø)
  • action myoclonia
    Ȱµ¿°£´ë¼º ±Ù°æ·Ã(Áõ)(¡­ÊàÓÛàõÐÉÌâÕýñø).
  • action potential
    Ȱµ¿ÀüÀ§(¡­ï³êÈ), Ȱµ¿Àü¾Ð(¡­ï³äâ)
  • action tremor
    ÇàÀ§ÁøÀü(ú¼êÓòÉïµ).
  • action, bactericidal
    »ì±ÕÀÛ¿ë
  • action, bacteriostatic
    Á¤±ÕÀÛ¿ë
  • additive action
    ºÎ°¡ÀÛ¿ë.
  • adverse action
    À¯ÇØ(êóúª)ÀÛ¿ë.
  • after action
    ÈÄ(¼Ó)(ý­(áÙ))ÀÛ¿ë.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • all-or-none law =all-or-none principle
    ´Ù³Ä ¾Æ´Ï³ÄÀÇ ¹ýÄ¢, ½Ç¹«À²
  • epigenetic principle
    °³Ã¼½Å»ý¿øÄ¢
  • follicle stimulating principle
    ³­Æ÷ÀڱؼººÐ(Õ°øàí©Ð½à÷ÝÂ).
  • glycotropic principle
    ´çģȭ¼º ¼ººÐ(ÓØöÑûúàõà÷ÝÂ).
  • isohydric principle
    µî¼ö¼Ò(Ôõâ©áÈ)À̿³óµµÀÇ ¿øÄ¢(ê«öÎ).
  • luteinizing principle
    Ȳüȭ¼ººÐ(üÜô÷ûù àõÝÂ).
  • natriuretic factor =n. principle
    ³ªÆ®·ý¹è¼³ÃËÁøÀÎÀÚ.
  • neutral principle
    Áß¼º¼ººÐ.
  • nirvana principle
  • organic principle
    À¯±â¼ººÐ(¡­à÷ÝÂ).
  • pleasure principle
    Äè¶ô¿øÄ¢, ÃæÁ·¿ø¸®(õöðë ê«ìµ).
  • priming principle
    ÃæÁø¿ø¸®, »çÀü¿¹ºñÁ¤ ÁÖ¹ý.
  • principle
    ¿ø¸®(ê«×â)
  • principle of convergence
    ÆøÁÖ¿øÄ¢(ÜßñÍ ê«öÎ).
  • principle of divergence
    ¹ß»ê¿øÄ¢(ۡߤ ê«öÎ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • photochemical action spectrum
    ±¤È­ÇÐÀÛ¿ë(ÎÃûùùÊíÂéÄ) ½ºÆåÆ®·³
  • photodynamic action
    ±¤¿ªÇÐ ÀÛ¿ë(ÎÃÕôùÊíÂéÄ)
  • protein-sparing action
    ´Ü¹éÁú Àý¾à ÀÛ¿ë(Ó±ÛÜòõï½å³íÂéÄ)
  • specific dynamic action
    ƯÀÌ µ¿Àû ÀÛ¿ë(÷åì¶ÔÑîÜíÂéÄ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
DAT delayed-action tablet; dementia Alzheimer's type; dental aptitude test; diacetylthiamine; diet as to...
FAP familial adenomatous polyposis; familial amyloid polyneuropathy; fatty acid polyunsaturated; fatty a...
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
VAT variable antigen type; ventricular accommodation test; ventricular activation time; vesicular amine ...
ECG Electro-Cardio-Graphy(-Gram); ½ÉÀüµµ
   = EKG
  1. Conducting System Structu...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PLS Partial Least Squares
PLS Partial least square regression
RLS recursive least squared
WLS Weighted least-squares
GLS generalized least squares
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • action mechanism
    ÀÛ¿ë ±âÀü
    ¾î¶² ±â´ÉÀÌ ÀϾ°Ô µÇ´Â °úÁ¤°ú °æ°ú.
  • action onset
    ÀÛ¿ë °³½Ã
  • action potential
    Ȱµ¿ ÀüÀ§, Ȱµ¿ Àü¾Ð
    ±ÙÀ°¼¼Æ÷ ¶Ç´Â ½Å°æ¼¼Æ÷°¡ ÈïºÐÇÒ ¶§ »ý±â´Â Àü±âÀû Ȱ¼ºÀ¸·Î¼­, Àü±âÀû, È­ÇÐÀû, ±â°èÀû ÀÚ±Ø ¹× ¿Âµµº¯È­ µî¿¡ ÀÇÇÏ¿© »ý±ä´Ù°í »ý°¢Çϰí ÀÖ´Ù.
  • action variable
    ÀÛ¿ë º¯¼ö
  • adverse action
    À¯ÇØÀÛ¿ë
  • analgetic action
    ÁøÅë ÀÛ¿ë
  • antagonistic action
    ±æÇ× ÀÛ¿ë
  • antidiuretic action
    Ç×ÀÌ´¢ÀÛ¿ë
  • antimicrobial action
    Ç×±Õ ÀÛ¿ë
  • antinociception action
    Ç×Ä§ÇØ¼ö¿ë¼º ÀÛ¿ë, Ç×À¯ÇØ ¼ö¿ë¼º ÀÛ¿ë
  • antipyretic action
    ÇØ¿­ ÀÛ¿ë
  • antispasmodic action
    Áø°æÀÛ¿ë
  • bactericidal action
    »ì±Õ ÀÛ¿ë, »ì±Õ¼º
    1. ¹ÚÅ׸®¾Æ¸¦ Á×ÀÌ´Â Çö»ó. ÀÌ ¿ë¾î´Â Á¾Á¾ Ç×»ýÁ¦ÀÇ ¼º°ÝÀ» ¼³¸íÇϴµ¥ »ç¿ëµÈ´Ù. 2. È­Çпä¹ýÁ¦, ¼Òµ¶Á¦ Áß¿¡´Â ¹Ì»ý¹°À» ¼Ò¸ê½ÃŰ´Â ÀÛ¿ëÀÌ ÀÖ´Ù. ÀÌ¿¡ ´ëÇØ ¾î¶² ¾àÁ¦¿¡ ´ëÇØ ±ÕÀÇ Áõ½ÄÀÌ ¾ïÁ¦µÇ´Âµ¥ ¾àÁ¦¸¦ Á¦°ÅÇÏ¸é ´Ù½Ã Áõ½ÄÇÏ´Â °ÍÀ» Áõ±Õ ÀÛ¿ëÀ̶ó ÇÑ´Ù.
  • bacteriostatic action
    Á¤±Õ ÀÛ¿ë
    ¼¼±ÕÀÇ ¹ßÀ° ¶Ç´Â Áõ½ÄÀ» ¾ïÁ¦ÇÏ´Â ÀÛ¿ë.
  • biological action
    »ý¹° ÀÛ¿ë
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
mass-action ratio The ratio of the product of all of the product concentrations divided by the product of all of the reactant concentrations of a particular reaction; when the reaction has been completed (i.e., t = ∞), then this ratio is equal to the equilibrium constant.
(05 Mar 2000)
mass action theory That large areas of brain tissue function as a whole in learned or intelligent action.
(05 Mar 2000)
mass action transmission <epidemiology> Transmission of infection which occurs at a rate directly proportional to the number or density of both susceptibles and infecteds present.
Some authors reserve the name mass action for transmission processes of the form b X Y/N , which we associate with STD-type transmission, and describe transmission rates of the form b X Y , as pseudo-mass action ; the two are equivalent if the population size is unchanging.
(05 Dec 1998)
cumulative action The condition in which repeated administration of a drug may produce effect's that are more pronounced than those produced by the first dose.
Synonym: cumulative action.
(05 Mar 2000)
salt action Any physicochemical effect produced by hypertonic concentrations of osmotically active electrolytes.
(05 Mar 2000)
prolonged action tablet sustained action tablet
sparing action The manner in which a nonessential nutritive component, by its presence in the diet, lowers the dietary requirement for an essential component; thus, nonessential l-cysteine spares essential l-methionine and nonessential l-tyrosine spares essential l-phenylalanine.
Synonym: sparing phenomenon.
(05 Mar 2000)
specific action The action of a drug or a method of treatment which has a direct and especially curative effect upon a disease, e.g., the action of vitamin B12 in pernicious anaemia.
(05 Mar 2000)
specific dynamic action The increase of heat production caused by the ingestion of food, especially of protein.
(05 Mar 2000)
delayed-action preparations Dosage forms of a drug that act over a period of time.
(12 Dec 1998)
thermogenic action Increase of heat production of the body, as by the thyroid hormone.
Synonym: thermogenic action.
(05 Mar 2000)
law of mass action <chemistry> This law states that the rate of a given chemical reaction is proportional to concentration of the reactants.
(09 Oct 1997)
active principle A constituent of a drug, usually an alkaloid or glycoside, upon the presence of which the characteristic therapeutic action of the substance largely depends.
(05 Mar 2000)
antianaemic principle The material in liver (and certain other tissues) that stimulates haemopoiesis in pernicious anaemia; for practical purposes, the antianaemic effect of extracts from such tissues is approximately equivalent to the content of vitamin B12.
(05 Mar 2000)
azygos vein principle A principle based on the observation that animals can survive prolonged vena caval occlusion without sequelae: if blood from the azygos vein alone is permitted to enter the heart, patients are perfused during cardiac and pulmonary bypass at flows much less than the normal resting cardiac output.
Synonym: low flow principle.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • action
    ¿òÁ÷ÀÓ,Çൿ,µ¿ÀÛ
  • action
    Ȱµ¿;ÀÛ¿ë;Çൿ;ÇàÀ§;µ¿ÀÛ;ÀÛ¿ë;¼Ò¼Û;ÀüÅõ;¼Ò¼³ÀÇ ÁٰŸ® Àü°³
  • civil action
    ¹Î»ç¼Ò¼Û
  • class action
    (°øµ¿ ÇÇÇØÀÚµéÀÇ)Áý´Ü ¼Ò¼Û
  • contact action
    Á¢ÃËÀÛ¿ë
  • covert action(operation)
    (°æÂû.Á¤º¸ºÎÀÇ)ºñ¹Ð°øÀÛ;ºñ¹Ðøº¸È°µ¿
  • cross action
    ¹Ý´ë ¼Ò¼Û;¹Ý¼Ò
  • delaying action
    Áö¿¬ Àü¼ú ÀÇ
  • direct action
    Á÷Á¢ Çൿ ±Ç¸®¸¦ À§ÇÑ ÆÄ¾÷(µ¥¸ð,½Ã¹ÎÀû ÀúÇ× µî)
  • disengaging action
    (±º)±³Àü ȸÇÇ;ÀÚ¹ßÀû ö¼ö
  • evasive action
    (Àü½Ã¿¡ ¼±¹Ú,Ç×°ø±â°¡ ÃëÇÏ´Â)ȸÇÇ Çൿ
  • friendly action
    ¿ìÈ£Àû ¼Ò¼Û
  • industrial action
    ³ëµ¿ÀÚÃøÀÇ ÀïÀÇ ÇàÀ§
  • mass action
    Áú·® ÀÛ¿ë
  • nocover action
    ³ëµ¿ÀïÀÇ ÁßÀÎ Á¶ÇÕ¿ø ¸òÀÇ ÀÏÀ» ÇÏÁö ¾ÊÀ½
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á